Filed with the SEC on · Summarized by InvestorsBot
Michael J. Farrell, ResMed’s chairman and CEO and a director, sold 4,991 shares of common stock on Sept. 8 at $222.44 per share, for approximately $1.11 million. He owned 466,256 shares after the transaction.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeResMed starts $450 million accelerated share repurchase with Citibank
8-K · September 1, 2026
ResMed appoints Carol Burt as lead director as Ron Taylor plans retirement
8-K · August 17, 2026
ResMed Names Carol Burt Lead Director as Ron Taylor Plans Board Retirement
8-K · August 17, 2026
ResMed replaces KPMG with PwC as independent auditor
8-K · August 17, 2026
ResMed CEO Michael Farrell sells $1.03M in stock
Form 4 · Insider Trade · August 11, 2026
ResMed filed an 8‑K (Item 9.01) attaching a press release dated Jan 29, 2026 reporting results of…
8-K · January 29, 2026